Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer

Rates of grade 3-4 toxicity with carboplatin and paclitaxel chemotherapy range 26-84%. Interventions to reduce toxicity are needed. Short term fasting protects against toxic effects of chemotherapy without decreasing efficacy. In a prospective clinical trial of breast cancer patients randomized to FMD or regular diet during chemotherapy, less antiemetic was required in the FMD group; radiographic and pathologic responses were better in this group. This trial tests whether platinum-taxane chemotherapy combined with a FMD in advanced and recurrent ovarian, fallopian tube and primary peritoneal cancer patients is associated with decreased toxicity and/ or improved tumor response to therapy.

NCT Number	NCT05921149
Lead Sponsor	Endeavor Health Collaborators: L-Nutra Inc
Conditions	Ovarian Cancer, Chemotherapeutic Toxicity
Enrollment	170 participants
Start Date	2024-05-25
Primary Completion	2028-06-01 (estimated)
Study Completion	2031-06-01 (estimated)
Updated on ClinicalTrials.gov	2024-05-07